STOCK TITAN

Biote Corp. - BTMD STOCK NEWS

Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.

Biote Corp. (BTMD) operates in the specialized field of hormone optimization, offering growth practice-building solutions. The company's primary focus is to empower Biote-certified practitioners with the tools and knowledge required to establish, build, and effectively implement hormone optimization programs. These programs are designed to provide personalized solutions tailored to individual patient needs.

Biote Corp. provides a comprehensive suite of components to its practitioners, including training, marketing support, and ongoing education. This holistic approach ensures that practitioners are well-equipped to deliver high-quality care in the hormone optimization space. The company's commitment to education and support is a key differentiator, enabling practitioners to stay at the forefront of this rapidly evolving field.

Recent achievements by Biote Corp. include expanding its network of certified practitioners and forging new partnerships aimed at enhancing its service offerings. The company continues to invest in research and development to improve its products and services, ensuring that they meet the highest standards of efficacy and safety.

Financially, Biote Corp. has demonstrated steady growth, driven by the increasing demand for hormone optimization solutions. The company's strategic initiatives and robust business model have positioned it well to capitalize on emerging opportunities in the healthcare sector.

For those interested in the latest updates and developments from Biote Corp., the company regularly releases news and updates, which are accessible through various channels.

Rhea-AI Summary

Biote (NASDAQ: BTMD) reported its Q2 2024 financial results, highlighting revenue of $49.2 million and a gross profit margin of 68.9%, up from 67.9% last year. Procedure revenue grew by 7.8%, reaching $38.4 million. The company faced a net loss of $(10.5) million, an improvement from a $(13.1) million loss in Q2 2023. Adjusted EBITDA was $12.7 million, down from $14.5 million a year earlier, due to increased sales and marketing investments.

Biote expanded its clinic network by 30% in the first half of 2024 and continued rolling out its BioteRx suite of hormone and wellness therapies, now in approximately 600 clinics. The company settled litigation with its founder, repurchasing 18.4 million shares. Guidance for 2024 remains unchanged, with revenue expected between $200-$204 million and Adjusted EBITDA between $60-$63 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.91%
Tags
-
Rhea-AI Summary

Biote Corp. (Nasdaq: BTMD), a leader in preventive health care through personalized hormone optimization and therapeutic wellness, has announced its upcoming second quarter 2024 financial results release. The company will disclose its financial performance on Thursday, August 8, 2024, after market close, followed by a conference call at 5:00 p.m. ET the same day.

Investors and interested parties can access the conference call by dialing (844) 481-2820 (U.S. toll-free) or (412) 317-0679 (International). A live webcast of the call will also be available. Following the event, a replay of the webcast will be accessible on the Events page of Biote's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences earnings
-
Rhea-AI Summary

Biote (NASDAQ: BTMD) has reached a $60 million agreement with stockholder Marci M. Donovitz to resolve ongoing litigation. The company will repurchase approximately 8.3 million shares and cancel around 4.0 million earnout shares owned by Ms. Donovitz. The repurchases, averaging $7.23 per share, will be executed over a three-year schedule. This settlement aligns with Biote's capital allocation strategy and aims to enhance long-term shareholder value. Biote's management believes this transaction represents an advantageous use of capital, eliminating future earnout obligations and consolidating share control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.44%
Tags
none
Rhea-AI Summary

Biote reported solid financial performance in the first quarter of 2024, with revenue reaching $46.8 million, a 4.4% increase from the prior year. Procedure revenue grew by 6.6%, while the gross profit margin improved to 71.4%. The company reported a net loss of $(5.8) million, representing a net loss margin of (12.4)%. Adjusted EBITDA increased by 8.0% to $14.2 million. Biote reaffirmed its 2024 financial guidance, expecting revenue of $200-$204 million and Adjusted EBITDA of $60-$63 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
-
Rhea-AI Summary

Biote Corp. (NASDAQ: BTMD) has settled outstanding litigation with its founder, Dr. Gary S. Donovitz, by repurchasing all of his 18.4 million shares at $4.17 per share. The Settlement Agreement includes mutual claims release, termination of advisory agreement, non-compete and non-solicitation agreements, and a voting agreement. The company plans to repurchase shares over a three-year schedule for a total of approximately $76.9 million to enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
Biote Corp. (Nasdaq: BTMD) announced the release of its first-quarter 2024 financial results on May 7, 2024, after the market closes. A conference call to discuss the results will be held at 5:00 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary
Biote (BTMD) announced financial results for Q4 and full year 2023, showcasing revenue growth, increased procedure revenue, and gross profit margin improvements. The company expanded its practitioner network and launched BioteRx products. They also repurchased founder shares and initiated a $20M share repurchase program. Despite a net loss in 2023, adjusted EBITDA and EBITDA margin increased. The 2024 financial outlook predicts revenue of $200-$204 million and adjusted EBITDA of $60-$63 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.91%
Tags
-
Rhea-AI Summary
Biote Corp. (BTMD) announces the release of its fourth-quarter and full-year financial results on March 12, 2024, followed by a conference call to discuss the outcomes. The company focuses on personalized hormone optimization and therapeutic wellness solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
-
Rhea-AI Summary
Biote Corp. (BTMD) announces the repurchase of approximately 18.4 million Class A shares and Paired Interests at $4.17 per share, resolving litigation with founder Dr. Gary S. Donovitz. The settlement includes mutual claims release, non-compete agreements, and a voting agreement. The repurchase, totaling $76.9 million, aims to enhance shareholder value and strengthen Biote's position in therapeutic wellness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
buyback
Rhea-AI Summary
Biote Corp. (BTMD) has announced a $20 million share repurchase program, marking the company's first authorization for share repurchases. The program grants management the authority to repurchase outstanding shares of the common stock through various means. CEO Terry Weber expressed confidence in the company's growth opportunity and business outlook, citing a strong balance sheet to support opportunistic share repurchases. The timing and extent of repurchases will be at the discretion of management, with no obligation to repurchase any specific amount or number of shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
buyback

FAQ

What is the current stock price of Biote (BTMD)?

The current stock price of Biote (BTMD) is $5.73 as of September 12, 2024.

What is the market cap of Biote (BTMD)?

The market cap of Biote (BTMD) is approximately 177.6M.

What does Biote Corp. do?

Biote Corp. operates in the hormone optimization space, providing tools and support for practitioners to implement personalized hormone optimization programs.

Who are Biote-certified practitioners?

Biote-certified practitioners are healthcare professionals trained and certified by Biote Corp. to deliver hormone optimization solutions.

What kind of support does Biote Corp. provide to practitioners?

Biote Corp. offers training, marketing support, and ongoing education to ensure practitioners can successfully implement hormone optimization programs.

What recent achievements has Biote Corp. made?

Recent achievements include expanding its network of practitioners and forging new partnerships to enhance service offerings.

How does Biote Corp. ensure the quality of its hormone optimization solutions?

Biote Corp. invests in research and development to continually improve the efficacy and safety of its products and services.

What is Biote Corp.'s financial condition?

Biote Corp. has shown steady growth driven by the increasing demand for hormone optimization solutions and strategic business initiatives.

How can I stay updated on Biote Corp.'s latest news?

Biote Corp. regularly releases news and updates, available through various channels to keep interested parties informed.

What are the core components provided by Biote Corp. to practitioners?

Biote Corp. provides training, marketing support, and ongoing education as part of its comprehensive suite of components for practitioners.

Why is hormone optimization important?

Hormone optimization is important for maintaining balance in the body, which can improve overall health and well-being.

Who can benefit from Biote Corp.'s hormone optimization programs?

Patients seeking personalized hormone optimization to address their specific health needs can benefit from Biote Corp.'s programs.

Biote Corp.

Nasdaq:BTMD

BTMD Rankings

BTMD Stock Data

177.60M
32.58M
27.7%
61.95%
4.13%
Medical Care Facilities
Medicinal Chemicals & Botanical Products
Link
United States of America
IRVING